Thermo Fisher Scientific's results for the fourth quarter and the full year of 2024 were better than anticipated, showing growth in both revenue and profits, which could lead to a 12% internal rate of return in the long run. The company has effectively allocated capital, returning $4.6 billion to shareholders and making strategic acquisitions, which enhances its growth and the potential for its undervalued stock. Although the guidance is not very strong, Thermo Fisher's leadership in life sciences and pharmaceuticals, along with an expected 11% annual earnings growth, suggests a positive long-term future.
Daniel Loeb is a smart billionaire investor who has put his money into various market conditions.
Thermo Fisher Scientific Inc. (NYSE:TMO) will participate in the 45th Annual TD Cowen Healthcare Conference Call on March 3, 2025, at 9:10 AM ET. The company will be represented by Marc Casper, who is the Chairman, President, and CEO. Daniel Brennan from TD Cowen will also be part of the conference call.
The main U.S. stock market indexes showed mixed results following a disappointing consumer confidence report and losses from some significant technology companies.
Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has released a report titled "Laboratory Supplies Market - Forecasts from 2025 to 2030." The global market for laboratory supplies is expected to grow at a rate of 7.44% annually, rising from US$47.531 billion in 2025 to US$68.044 billion by 2030. This growth is driven by advancements in science and technology, increased research activities, and a higher demand for specialized supplies in healthcare and pharmaceuticals, particularly in areas like genomics and biotechnology.
In the fourth quarter of 2024, Thermo Fisher experienced growth in all areas, and it is expected that earnings per share will increase by 6.6% in 2025 due to improved profit margins. Although the industry is generally highly valued, Thermo Fisher's stock is priced lower than competitors like Danaher, thanks to its unique size and range of products. A careful analysis suggests that Thermo Fisher is fairly priced, but its strong position in the industry and comparison to other companies justify a recommendation to buy.
Thermo Fisher Scientific (TMO) saw its shares increase on Thursday after the company's fourth-quarter results exceeded what analysts had predicted.
We have just released a list of the 12 Best Stocks to Buy in 2025 for those new to investing. In this article, we will examine how Thermo Fisher Scientific Inc. (NYSE:TMO) compares to other top beginner stocks for 2025. Additionally, we will discuss the stock market predictions for 2025, as shared by Tom Lee from Fundstrat Global on December 12.
Thermo Fisher Scientific Inc. (NYSE:TMO) will hold its Q4 2024 Earnings Conference Call on January 30, 2025, at 8:30 AM ET. The call will feature company representatives including Rafael Tejada, Marc Casper, and Stephen Williamson, along with participants from various financial institutions. The operator, Ezra, will welcome everyone to the call.
Thermo Fisher Scientific (TMO) reported quarterly earnings of $6.10 per share, which is higher than the Zacks Consensus Estimate of $5.93 per share. This is an increase compared to earnings of $5.67 per share from the same period last year.